Articles in this Issue

• 

  Make drugs, not war

  Friday, May 08, 2026
  Developers who treat China’s rise as a strategic opportunity — both for partnership and as a wakeup call to address inefficiencies in Western systems — will be best positioned to take home the ... read more
• 

  Ten best practices for developing ophthalmic CGTs

  Wednesday, May 20, 2026
  Here are 10 best practices that can help drug developers avoid delays, protect data quality, and meet regulatory, clinical and manufacturing expectations. read more
• 

  Avoiding CMC pitfalls

  Tuesday, June 23, 2026
  A clear CMC roadmap is critical as global regulators expect to see not only a snapshot of current controls but a clear path showing how a process will mature and scale throughout development and ... read more
• 

  All the CAR-T in China

  Wednesday, June 10, 2026
  The real risk is not that one country pulls ahead. It’s that friction — political, regulatory or economic — slows the system as a whole. read more
• 

  Placenta as the missing link

  Monday, June 15, 2026
  When you combine an ethical, plentiful human tissue source with disciplined manufacturing and true codevelopment partnerships, you get a realistic way to scale human-derived biomaterials. read more
• 

  Refining the molecular blueprint of in vivo CAR-T

  Thursday, June 18, 2026
  Laboratory management software can’t build a perfectly optimized construct for an in vivo CAR-T cell therapy, but it can make the lives of the scientists doing so considerably easier. read more